ClinicalTrials.gg
RecruitingNCT07626281Updated Oct 5, 2026

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

A Phase 1 interventional study of Inclisiran formulation containing PS80 and Currently marketed inclisiran formulation in Inclisiran Formulation, sponsored by Novartis Pharmaceuticals. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 5, 2026Enrollment updated3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a single 284 mg subcutaneous (SC) administration.

Read the detailed description

This is a randomized, single-dose, open-label, parallel-group, study to evaluate the PK, safety, and tolerability of inclisiran 284 mg. The study drug will be administered as a single SC injection to the abdomen administered as 2 different formulations (the marketed formulation and a test formulation containing PS80). Approximately 152 adult participants (76 per formulation) with elevated serum LDL-C, but otherwise healthy, are planned to be enrolled.

The duration of the study for each participant will be approximately 118 days including the screening, up to 28 days, baseline period, and treatment period of 90 days.

02

Conditions studied

  • Inclisiran Formulation

Keywords

  • Inclisiran containing polysorbate 80
  • healthy male and female participants
  • safety
  • tolerability
  • pharmacokinetics
  • pharmacodynamics
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female (non-) participants between 18 and 60 years of age (inclusive) with fasting serum LDL-C between 100 and 189 mg/dL (2.6 to 4.89 mmol/L) and fasting triglyceride \<400 mg/dL (\<4.52 mmol/L) that are not on statin or any other lipid lowering therapy.
  • (BMI) between 18 and 35 kg/m2, inclusive, at screening with a body weight of at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • Participants with homozygous and heterozygous familial hypercholesterolemia will be excluded.
  • Historical or current use of any statin (i.e. study participants must be statin naive), other oral LDL-C-lowering medication or supplements that in investigators' judgment may affect serum LDL-C levels.

Other protocol inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Active comparator
    Arm A (inclisiran - currently marketed formulation)

    Inclisiran 284 mg × 1 single dose on Day 1

    Drug: Currently marketed inclisiran formulation

  • Experimental
    Arm B (inclisiran - formulation containing PS80)

    Inclisiran 284 mg × 1 single dose on Day 1

    Drug: Inclisiran formulation containing PS80

Interventions

06

What researchers measure

Primary outcomes

  1. Primary plasma PK parameters: Cmax

    Cmax = maximum observed plasma concentration

    Time frame: Day 1, Day 2, Day 3 and Day 4

  2. Primary plasma PK parameters: AUClast

    AUClast = AUC from time zero to the last measurable concentration sampling time

    Time frame: Day 1, Day 2, Day 3 and Day 4

  3. Primary plasma PK parameters: AUCinf

    AUCinf = AUC from time zero to infinity

    Time frame: Day 1, Day 2, Day 3 and Day 4

  4. Additional PK parameters: AUC0-24hr

    AUC0-24hr = AUC from time zero to 24 hours

    Time frame: Day 1, Day 2, Day 3 and Day 4

  5. Additional PK parameters: Tmax

    Tmax = time to reach maximum plasma concentration

    Time frame: Day 1, Day 2, Day 3 and Day 4

  6. Additional PK parameters: T1/2

    T1/2 = elimination half-life

    Time frame: Day 1, Day 2, Day 3 and Day 4

  7. Additional PK parameters: CL/F

    CL/F = total body clearance

    Time frame: Day 1, Day 2, Day 3 and Day 4

  8. Additional PK parameters: Vz/F

    Vz/F = apparent volume of distribution

    Time frame: Day 1, Day 2, Day 3 and Day 4

Secondary outcomes

  1. Number of participants with AEs

    Number of participants with AEs, including abnormal vital signs, ECGs, injection site reactions and safety laboratory parameters.

    Time frame: Up to Day 90

07

Study locations

6 of 6 sites recruiting
  • ICON Early Clin Services Lenexa
    Lenexa, Kansas 66219, United States
    Recruiting
    • Patrick Yao · Principal investigator
  • Lenexa Research Unit
    Lenexa, Kansas 66219, United States
    Recruiting
  • ICON Early Clin Service San Antonio
    San Antonio, Texas 78209, United States
    Recruiting
    • Chinonye Ogbonnaya-Odor · Principal investigator
  • Cardiovasular Renal Metabolism
    San Antonio, Texas 78232, United States
    Recruiting
  • ICON Early Clinical Services SLC
    Salt Lake City, Utah 84124, United States
    Recruiting
    • Julia Garcia · Principal investigator
  • Salt Lake City Research Unit
    Salt Lake City, Utah 84124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Dec 21, 2026
CompletionEst.
Dec 21, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • ICON Early Clin Services Lenexa · Lenexa, United States
  • ICON Early Clin Service San Antonio · San Antonio, United States
  • ICON Early Clinical Services SLC · Salt Lake City, United States
Oct 5, 2026
Enrollment
120→152
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    3 sites added
    Show 3 added (3 United States)
    • ICON Early Clin Services Lenexa · Lenexa, United States
    • ICON Early Clin Service San Antonio · San Antonio, United States
    • ICON Early Clinical Services SLC · Salt Lake City, United States
    Enrollment 120→152
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07626281
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jun 9, 2026
Primary completion
Dec 21, 2026 (estimated)
Completion
Dec 21, 2026 (estimated)
Last update
Oct 5, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion